Manas AI CEO Siddhartha Mukherjee has cautioned that a universal cure for cancer remains unlikely in the near future, despite advances in immunotherapy, genetic sequencing and artificial intelligence. Speaking at the Hindustan Times Leadership Summit 2026, Mukherjee said significant progress had been made against breast cancer, leukaemias and lymphomas, but pancreatic cancer and several cancers affecting the stomach and intestinal tract remained major challenges. He highlighted a KRAS-targeting drug as a breakthrough for pancreatic cancer and other cancers, but said the idea of curing every type of cancer with a single treatment was mistaken. Mukherjee also warned about bias in medical AI, describing the problem as “bias in, bias out” or “Bibo”. He explained how randomised, blinded clinical trials help address human bias and said synthetic controls using historical or simulated data could potentially accelerate clinical trials.
E-Paper
